Shares of Arvinas ARVN plummeted earlier this week after the company and partner Pfizer announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback